Arrowhead Pharma Stock Price, News & Analysis

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has successfully completed enrollment for the Phase 2b ARCHES-2 clinical study of its investigational RNAi therapeutic, ARO-ANG3, targeting mixed dyslipidemia with over 180 participants. The trial aims to assess the safety and efficacy of various doses, with topline data expected in the first half of 2023. The study evaluates the ability of ARO-ANG3 to inhibit ANGPTL3, which plays a role in lipid metabolism. Results will inform future late-stage clinical trials.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated dosing in the AROC3-1001 Phase 1/2 clinical study for ARO-C3, an RNA interference therapeutic targeting complement component 3 (C3). This study evaluates ARO-C3's safety and effectiveness in treating complement-mediated diseases such as IgA nephropathy and paroxysmal nocturnal hemoglobinuria. The trial includes up to 62 subjects and aims to assess various dosing regimens. With promising preclinical data, Arrowhead expects ARO-C3 to address significant unmet medical needs in this therapeutic area.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced positive interim results from the Phase 1b AROHIF21001 trial for ARO-HIF2, targeting clear cell renal cell carcinoma (ccRCC). The study showed a significant reduction in HIF2α expression, with 9 out of 14 patients demonstrating decreased protein levels. In terms of safety, ARO-HIF2 was well-tolerated, with 12% of patients reporting anemia and hypoxia. The data, presented at the 2022 ASCO GU symposium, highlighted a 39% disease control rate across all cohorts, underscoring the potential of ARO-HIF2 as a therapeutic option in ccRCC.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported its financial results for Q1 2022, ending December 31, 2021. The company generated $27.4 million in revenue, an increase from $21.3 million in Q1 2021. However, operating expenses surged to $90.8 million, resulting in a net loss of $62.9 million or $0.60 per share. The company initiated the PALISADE Phase 3 study for ARO-APOC3, advanced two new candidates for pulmonary conditions, and secured a land deal for a new manufacturing facility in Wisconsin. A licensing agreement with GlaxoSmithKline for ARO-HSD was also established.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the closure of its exclusive license agreement with GlaxoSmithKline (LSE/NYSE: GSK), initially revealed on November 22, 2021. The transaction's closing was contingent upon meeting customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. This milestone marks a significant step in Arrowhead's collaboration with GSK, potentially impacting its product development and market position.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will hold a webcast and conference call on February 2, 2022, at 4:30 p.m. ET to discuss its financial results for the first quarter of fiscal 2022, ending December 31, 2021. Interested investors can access the live audio on the company’s website. A replay will be available afterward for 90 days. Arrowhead focuses on developing RNAi-based therapeutics, targeting diseases by silencing specific genes through its innovative RNA chemistries and delivery methods.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated the Phase 3 PALISADE study to evaluate the efficacy and safety of ARO-APOC3 in patients with familial chylomicronemia syndrome (FCS). ARO-APOC3, an RNA interference therapeutic, aims to inhibit apolipoprotein C3 production, critical for triglyceride metabolism. The study will involve approximately 60 participants and assess changes in triglyceride levels over 56 weeks. Previous studies indicated a significant triglyceride reduction of up to 91%. The company is also collaborating with Ambry Genetics for genetic testing for at-risk patients.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has acquired 13 acres in Verona Technology Park, Wisconsin, where it plans to build a drug manufacturing facility (140,000 sq. ft.) and a laboratory/office space (115,000 sq. ft.). The investment, estimated between $200 million and $250 million, aims to create about 250 jobs. Construction is set to begin in Q1 2022, with lab completion expected in Q1 2023 and manufacturing in Q4 2023. This expansion underscores Arrowhead’s commitment to the Wisconsin biotech ecosystem and supports its growing pipeline of RNAi medicines.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the approval of inducement grants for 24 new employees by its Compensation Committee on December 14, 2021. The grants, totaling up to 87,000 restricted stock units, are meant to incentivize employment and are outside the company’s stockholder-approved equity incentive plans. These units will vest annually over four years, reflecting the company's commitment to attracting talent in its mission to develop innovative RNA interference therapies for intractable diseases.